4-11岁幼年起病自身免疫炎症性风湿病患儿接种BNT162b2 mRNA新冠疫苗的纵向安全性与有效性:一项前瞻性多中心研究
这项在以色列4个三级儿童风湿病中心开展的前瞻性纵向多中心研究,纳入31例自身免疫炎症性风湿病(AIIRD)患儿和45名免疫正常对照,于2021年11月至2022年12月接种至少2剂BNT162b2 mRNA新冠疫苗。结果显示两组不良事件发生率相近、AIIRD病情活动保持稳定且低水平、突破性感染率相近,作者认为该疫苗在4-11岁AIIRD患儿中安全性极佳、有效性两组相似。
要点
- AIIRD患儿接种后不良事件以轻度或无为主,两组发生率相近。
- 接种后AIIRD病情活动保持稳定且低水平。
- 两组突破性感染率相近,未见重症疾病。
核心结论
- 作者认为,BNT162b2新冠疫苗在4-11岁AIIRD患儿和健康对照中安全性极佳,两组有效性相似。
研究设计与样本
- 前瞻性、纵向、多中心研究,2021年11月至2022年12月在以色列4个三级儿童风湿病中心开展。
- 纳入31例4-11岁AIIRD患儿与45名基线特征相近的免疫正常对照,受试者至少接种2剂疫苗。
- 安全性分析包括不良事件与疾病活动度指标;有效性以COVID-19感染率评估;免疫原性在部分受试者中以抗受体结合域抗体滴度评估。
主要发现
- 首剂后不良事件率AIIRD组27例(60%)vs 对照组14例(45.2%),p=0.2977;第二剂后AIIRD组22例(49.0%)vs 对照组18例(58.1%),p=0.5799。
- 接种后AIIRD病情活动保持稳定且低水平。
- 突破性COVID-19感染率AIIRD组15例(48.4%)vs 对照组25例(55.6%),p=0.7029。
- AIIRD组所有报告COVID-19感染者均有症状,对照组18例(72%)有症状(p=0.033),症状总体轻微,无重症疾病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This prospective, longitudinal, multicenter study assessed the safety and efficacy of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine among children 4-11 years-old with autoimmune inflammatory rheumatologic disease (AIIRD), compared to healthy controls. The study was conducted from 11/2021-12/2022 at 4 tertiary pediatric rheumatology units in Israel. Participants received at least 2 vaccine doses. Safety analysis included adverse events and disease activity measures. Efficacy was assessed by COVID-19 infection rates. Immunogenicity was evaluated in a subset of participants using anti- receptor binding domain antibody titers. Thirty-one children with AIIRD and 45 immunocompetent controls with similar baseline characteristics were included. Safety profile was favorable, with mild or no adverse events reported. The adverse event rates were similar in the AIIRD and control groups after the first (27 (60 %) vs. 14 (45.2 %), p = 0.2977) and the second vaccine doses (22 (49.0 %) vs. 18 (58.1 %), p = 0.5799), respectively. AIIRD activity remained stable and low after vaccination. Breakthrough COVID-19 infection rates were similar between groups, with 15 (48.4 %) in the AIIRD vs. 25 (55.6 %) in the control group (p = 0.7029). All reported COVID-19 infections in the AIIRD group and 18 (72 %) in the control group were symptomatic (p = 0.033), although symptoms were generally mild, with no severe disease. The safety of the BNT162b2 COVID-19 vaccine was excellent in children ages 4-11 years with AIIRD and healthy controls. Efficacy between groups was similar.
引用
- Eviatar T, Ziv A, Oved A, et al. Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study. Vaccine. 2024. PMID: 39423454. doi:10.1016/j.vaccine.2024.126426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。